Goserelin

Peptide

Approvedregulatory verdict

Evidence outlook

Approved: HR+/HER2- Metastatic Breast Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (3)
US
  • Stage B2-C Prostatic Carcinoma ZOLADEX is indicated for use in combination with flutamide for the management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate. Treatment with ZOLADEX and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy [see Dosage and Administration ( 2.1 ) and Clinical Studies ( 14.1 )].
  • Endometrial Thinning ZOLADEX is indicated for use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding [see Dosage and Administration ( 2.4 ) and Clinical Studies ( 14.4 )].
  • Endometriosis ZOLADEX is indicated for the management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy. Experience with ZOLADEX for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months [see Dosage and Administration ( 2.3 ) and Clinical Studies ( 14.3 )].
Product first approved 1989Outside this platform's coverageFDA label
Featured evidence outside this drug's tracked markets:NCT00309478 · Early Breast Cancer · Phase 3 · mixed result · Partial signal

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (69)
HR+/HER2- Metastatic Breast Cancer
NCT02003209 · National Cancer Institute (NCI)
2014-02-18 – 2025-06-30 · HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
What this study did
NCT02344472 · Prof. Wolfgang Janni
2015-09 – 2025-01-31 · Metastatic Breast Cancer
What this study did
NCT03936933 · Eurofarma Laboratorios S.A.
2020-10-30 – 2025-01-30 · Breast Cancer
What this study did
NCT03664895 · Seoul National University Hospital
2018-09-03 – 2024-12-31 · Breast Cancer Invasive
What this study did
NCT04478266 · Sanofi
2020-10-14 – 2023-05-26 · Breast Cancer
What this study did
NCT05110170 · Luye Pharma Group Ltd.
2020-10-15 – 2022-06-24 · Breast Cancer
What this study did
NCT03096847 · Novartis Pharmaceuticals
2016-10-24 – 2020-02-06 · Advanced Metastatic Breast Cancer
What this study did
NCT00295646 · Austrian Breast & Colorectal Cancer Study Group
1999-06 – 2018-06-26 · Breast Cancer
What this study did
NCT01638247 · GBG Forschungs GmbH
2012-08 – 2018-05 · Male Breast Cancer
What this study did
NCT01073865 · AstraZeneca
2010-02-26 – 2017-11-20 · Breast Cancer
What this study did
NCT02483767 · Peking Union Medical College Hospital
2015-06 – 2016-11 · Breast Cancer
What this study did
NCT00068601 · SWOG Cancer Research Network
2003-10 – 2016-09 · Breast Cancer, Infertility, Menopausal Symptoms
What this study did
NCT00912548 · Korean Breast Cancer Study Group
2009-05 – 2015-12 · Breast Cancer
What this study did
NCT01530607 · King Faisal Specialist Hospital & Research Center
2009-11 – 2012-11 · Breast Cancer
What this study did
NCT00047099 · Ludwig-Maximilians - University of Munich
2001-08 – 2012-03 · Breast Cancer
What this study did
NCT00429403 · M.D. Anderson Cancer Center
2006-08 – 2010-07 · Breast Cancer
What this study did
Other / comorbidity
NCT07777263 · Dr. Tamim Niazi
2026-12 – 2040-12 · High Risk Prostate Cancer
What this study did
NCT04513717 · NRG Oncology
2021-01-21 – 2038-12-31 · Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
What this study did
NCT03678025 · SWOG Cancer Research Network
2018-09-24 – 2036-10-01 · Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
What this study did
NCT04423211 · ECOG-ACRIN Cancer Research Group
2020-10-08 – 2032-12-31 · Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
What this study did
NCT05781217 · Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
2023-03-14 – 2032-12 · Prostate Cancer, Salvage Radiotherapy, Biochemical Recurrence, Androgen Deprivation Therapy, Metastases-free Survival
What this study did
NCT00430183 · Alliance for Clinical Trials in Oncology
2007-05-08 – 2030-10 · Prostate Cancer
What this study did
NCT05827081 · Novartis Pharmaceuticals
2024-02-28 – 2030-09-20 · Early Breast Cancer
What this study did
NCT02535221 · Peking University
2015-07-29 – 2026-12-31 · Breast Cancer
What this study did
NCT02914158 · First Affiliated Hospital, Sun Yat-Sen University
2016-03-30 – 2025-12 · Breast Cancer
What this study did
NCT01546987 · Radiation Therapy Oncology Group
2012-05 – 2025-09-04 · Prostate Cancer
What this study did
NCT02132390 · Peking Union Medical College Hospital
2014-05 – 2024-05 · Breast Cancer, Chemotherapy Induced Amenorrhea, Ovarian Function Suppression
What this study did
NCT03936218 · Eurofarma Laboratorios S.A.
2020-09-30 – 2024-04-01 · Advanced Prostate Cancer
What this study did
NCT00541047 · University College, London
2007-11 – 2022-07-27 · Gastrointestinal Complications, Prostate Cancer, Sexual Dysfunction, Urinary Complications
What this study did
NCT03658213 · AstraZeneca
2020-03-31 – 2021-11-04 · Breast Cancer
What this study did
NCT03447132 · International Cancer Research Group, United Arab Emirates
2017-12-20 – 2021-07-20 · Breast Neoplasm Female
What this study did
NCT04563936 · Luye Pharma Group Ltd.
2020-01-06 – 2021-03-09 · Prostate Cancer
What this study did
NCT03054168 · University of Nottingham
2016-12-15 – 2019-02-15 · Sarcopenia, Muscle Hypotrophy, Muscle Atrophy
What this study did
NCT00002597 · Radiation Therapy Oncology Group
1994-10 – 2018-05-14 · Prostate Cancer
What this study did
NCT00004124 · SWOG Cancer Research Network
1999-10-15 – 2018-05-01 · Prostate Cancer
What this study did
NCT01352091 · Fudan University
2008-05 – 2018-04 · Breast Cancer
What this study did
NCT01712893 · Fudan University
2009-06 – 2017-08 · Breast Cancer
What this study did
NCT00769548 · Radiation Therapy Oncology Group
1995-04 – 2016-12 · Prostate Cancer
What this study did
NCT00439751 · Ontario Clinical Oncology Group (OCOG)
2007-04 – 2016-06 · Prostate Cancer
What this study did
NCT00021450 · European Organisation for Research and Treatment of Cancer - EORTC
2001-04 – 2016-01 · Prostate Cancer
What this study did
NCT00104715 · UNICANCER
2004-10-18 – 2015-12-15 · Prostate Cancer
What this study did
NCT00423475 · UNICANCER
2006-10 – 2015-03 · Prostate Cancer
What this study did
NCT00116220 · Dana-Farber Cancer Institute
1995-09 – 2015-02 · Prostate Cancer
What this study did
NCT00002580 · Scottish Cancer Therapy Network
started 1993-06 · Breast Cancer
What this study did
NCT00427245 · Anglo Celtic Cooperative Oncology Group
started 2004-08 · Breast Cancer, Infertility, Menopausal Symptoms
What this study did
Phase 2/3 (6)
Other / comorbidity
NCT06282588 · Cancer Research Antwerp
2023-12-13 – 2030-12-31 · Prostate Cancer
What this study did
NCT03070886 · NRG Oncology
2017-04-05 – 2030-10-31 · Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
What this study did
NCT04787744 · VA Office of Research and Development
2021-07-01 – 2029-03-30 · Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
What this study did
NCT05253066 · Shengjing Hospital
2022-02-25 – 2025-01-31 · Breast Neoplasms
What this study did
NCT03373708 · Zhiyong Yu
2017-12-20 – 2019-12-20 · Breast Cancer, Chemotherapy, Endocrine Breast Diseases
What this study did
NCT01218581 · Mansoura University
2005-12 – 2010-01 · the Efficacy of Aromatase Inhibitor vs. Gonadotrpins Releasing Hormone Agonists in Treating Premenopausal Women With Uterine Adenomyosis
What this study did
Phase 2 (99)
HR+/HER2- Metastatic Breast Cancer
NCT06953882 · Yale University
2025-07-09 – 2030-09 · HER2 Negative Breast Cancer
What this study did
NCT02624973 · Haukeland University Hospital
2016-04-15 – 2030-06 · Breast Cancer
What this study did
NCT07460752 · Mayo Clinic
2026-05-22 – 2029-06-21 · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Locally Advanced Hormone Receptor-Positive Breast Carcinoma
What this study did
NCT07158021 · University of Michigan Rogel Cancer Center
2026-01-22 – 2028-01-01 · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
What this study did
NCT05720260 · National Taiwan University Hospital
2023-01-17 – 2027-01-31 · Premenopausal Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
What this study did
NCT05594095 · Fudan University
2022-12-30 – 2026-12-01 · Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer, Advanced Breast Cancer
What this study did
NCT03822468 · Novartis Pharmaceuticals
2019-06-11 – 2024-08-30 · Breast Cancer
What this study did
NCT05163106 · University Hospital, Akershus
2022-12-01 – 2024-07-30 · Breast Cancer, HER2-negative Breast Cancer, ER-positive Breast Cancer, Locally Advanced Breast Cancer, Luminal A Breast Cancer, Luminal B Breast Cancer
What this study did
NCT02917005 · Hamdy A. Azim
2019-05-07 – 2023-12 · Metastatic Breast Cancer
What this study did
NCT05004142 · Ahon Pharmaceutical Co., Ltd.
2020-06-30 – 2023-06-30 · Breast Neoplasms
What this study did
NCT03007979 · Washington University School of Medicine
2017-06-15 – 2023-03-31 · Breast Cancer, Breast Carcinoma, Cancer of Breast, Malignant Tumor of Breast
What this study did
NCT01266213 · Samsung Medical Center
2010-12 – 2019-12 · Metastatic Breast Cancer, Estrogen Receptor Positive Tumor, Breast Cancer Nos Premenopausal
What this study did
NCT01989780 · Japan Breast Cancer Research Group
2014-01 – 2019-06 · Metastatic Breast Cancer
What this study did
NCT02313051 · Chinese Academy of Medical Sciences
2014-12 – 2017-12 · Metastatic Breast Cancer
What this study did
NCT02072512 · Hospital Affiliated to Military Medical Science, Beijing
2014-01 – 2016-12 · Metastatic Breast Cancer
What this study did
NCT00186121 · Stanford University
2000-10 – 2013-06 · Breast Cancer
What this study did
NCT01240941 · Vanderbilt-Ingram Cancer Center
2011-02 – 2012-12 · Metastatic Breast Cancer
What this study did
NCT01205685 · Vanderbilt-Ingram Cancer Center
2010-05 – 2011-07 · Hormone-sensitive Metastatic Breast Cancer
What this study did
NCT00532272 · National Cancer Center, Korea
2005-10 – 2010-08 · Metastatic Breast Cancer
What this study did
NCT00196846 · GBG Forschungs GmbH
2005-03 – 2010-03 · Breast Cancer
What this study did
NCT01013506 · Vanderbilt-Ingram Cancer Center
2009-08 – 2009-12 · Breast Cancer
What this study did
NCT00322348 · AstraZeneca
2006-04 – 2009-11 · Advanced Breast Cancer
What this study did
NCT00303524 · AstraZeneca
2006-02 – 2009-02 · Breast Cancer
What this study did
NCT00498901 · University of Washington
2007-02 – 2008-11 · Breast Cancer
What this study did
NCT00217659 · SWOG Cancer Research Network
2005-09 – 2007-01 · Breast Cancer
What this study did
NCT00235937 · AstraZeneca
2001-12 – 2006-12 · Breast Cancer
What this study did
NCT00010010 · NYU Langone Health
2000-06 – 2001-05 · Breast Cancer
What this study did
Other / comorbidity
NCT06348134 · University of Chicago
2025-03-18 – 2036-07-01 · Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, Breast Cancer
What this study did
NCT02476786 · Washington University School of Medicine
2017-01-17 – 2032-07-31 · Breast Cancer, Cancer of Breast, Breast Neoplasms, Cancer of the Breast
What this study did
NCT02603679 · Thomas Hatschek
2015-02 – 2031-12-31 · Early-Stage Breast Carcinoma, Estrogen Receptor Positive Tumor
What this study did
NCT06225284 · National Taiwan University Hospital
2024-08-22 – 2030-12 · Triple Negative Breast Cancer, Premenopausal Breast Cancer
What this study did
NCT03809000 · RTOG Foundation, Inc.
2019-04-15 – 2029-09-15 · Prostate Cancer
What this study did
NCT05582499 · Fudan University
2022-11-01 – 2029-09 · Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT06575257 · Xijing Hospital
2024-05-01 – 2029-05 · Prostate Cancer
What this study did
NCT06387056 · The First Affiliated Hospital of Xiamen University
2024-04-01 – 2029-04-01 · Locally Advanced Prostate Cancer, Oligometastatic Prostate Cancer
What this study did
NCT07801898 · The Second Hospital of Anhui Medical University
2026-09-30 – 2029-03-30 · Invasive Breast Cancer (Stage I-III)
What this study did
NCT02592083 · Thomas Hatschek
2015-10 – 2029-02 · Early-Stage Breast Carcinoma, Hormone Receptor Positive Tumor
What this study did
NCT06145308 · Peking Union Medical College
2023-08-15 – 2028-07-10 · Salivary Gland Carcinoma, Precision Therapy
What this study did
NCT01723774 · Washington University School of Medicine
2013-04-10 – 2027-11-07 · Breast Neoplasms
What this study did
NCT05513365 · Radboud University Medical Center
2022-09-27 – 2027-09 · Salivary Duct Carcinoma
What this study did
NCT06582446 · German Oncology Center, Cyprus
2024-09-16 – 2027-08-31 · Prostate Cancer
What this study did
NCT04734730 · City of Hope Medical Center
2021-05-04 – 2027-08-23 · Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
What this study did
NCT00544830 · City of Hope Medical Center
2006-08-07 – 2027-02-15 · PSA Level Greater Than Two, Stage IV Prostate Adenocarcinoma AJCC v7
What this study did
NCT01786265 · M.D. Anderson Cancer Center
2013-02-05 – 2027-02-01 · Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
What this study did
NCT03361735 · City of Hope Medical Center
2018-08-29 – 2027-01-06 · Prostate Adenocarcinoma
What this study did
Phase 1/2 (7)
Other / comorbidity
NCT07596212 · University of Illinois at Chicago
2026-09 – 2031-09 · Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder, Hormone Receptor Positive Breast Carcinoma, Breast Cancer
What this study did
NCT05003752 · German Oncology Center, Cyprus
2021-08-01 – 2027-08-01 · Prostate Adenocarcinoma, Radiation Toxicity
What this study did
NCT03587285 · Guangzhou University of Traditional Chinese Medicine
2018-09-23 – 2021-07-31 · Prostatic Neoplasms
What this study did
NCT00669162 · University of Kansas Medical Center
2012-08 – 2017-04 · Prostate Cancer
What this study did
NCT01163084 · National Cancer Institute (NCI)
2010-07-09 – 2012-06-01 · Prostate Adenocarcinoma, Stage IIA Prostate Cancer AJCC v7, Stage IIB Prostate Cancer AJCC v7
What this study did
NCT00653757 · Mayo Clinic
2002-03 – 2007-12 · Prostate Cancer
What this study did
NCT00003394 · Memorial Sloan Kettering Cancer Center
1998-04 – 2003-04 · Prostate Cancer
What this study did
Phase 1 (20)
HR+/HER2- Metastatic Breast Cancer
NCT07310420 · TerSera Therapeutics LLC
2026-10-20 – 2027-07-31 · Advanced Breast Cancer, Early Breast Cancer
What this study did
NCT02626507 · Hoffman Oncology
2016-01 – 2022-03-15 · Breast Cancer
What this study did
NCT02586675 · H. Lee Moffitt Cancer Center and Research Institute
2016-02-23 – 2021-10-27 · Breast Cancer, Breast Cancer - Female, Breast Cancer - Male
What this study did
NCT01240928 · Vanderbilt-Ingram Cancer Center
— · Metastatic Breast Cancer
What this study did
NCT01149356 · National Cancer Institute (NCI)
2010-10 – 2013-04 · Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
What this study did
Other / comorbidity
NCT02023463 · Thomas Jefferson University
2014-04-02 – 2040-01-01 · Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
What this study did
NCT05617885 · Praful Ravi, MB BCHir, MRCP
2023-08-09 – 2026-06-01 · Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer
What this study did
NCT07097259 · EMD Serono Research & Development Institute, Inc.
2025-07-21 – 2025-12-23 · Hypogonadism
What this study did
NCT00099086 · Medical University of South Carolina
2007-01-16 – 2023-12-13 · Prostate Cancer
What this study did
NCT05856630 · Luye Pharma Group Ltd.
2023-05 – 2023-12 · Prostate Cancer
What this study did
NCT05140512 · Luye Pharma Group Ltd.
2021-02-04 – 2021-11-26 · Prostate Cancer
What this study did
NCT04428684 · Peptigroupe Inc.
2018-10-29 – 2020-06-07 · Dysfunctional Uterine Bleeding
What this study did
NCT04060043 · CMX Research
2017-02-21 – 2018-01-02 · Prostate Cancer
What this study did
NCT00631527 · M.D. Anderson Cancer Center
2008-02 – 2015-01 · Prostate Cancer
What this study did
NCT00328614 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2003-03 – 2011-06 · Prostate Cancer
What this study did
NCT00482807 · University of Nebraska
2004-08-31 – 2010-03-09 · Prostate Cancer
What this study did
NCT00438321 · Massachusetts General Hospital
2006-09 – 2010-02-26 · Metabolic Syndrome
What this study did
NCT00512668 · National Cancer Institute (NCI)
2007-09 – 2008-01 · Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
What this study did
NCT00026377 · University of Chicago
2001-11 – 2003-04 · Prostate Cancer
What this study did
Phase 4 (19)
HR+/HER2- Metastatic Breast Cancer
NCT05161195 · Novartis Pharmaceuticals
2022-07-07 – 2030-08-14 · Metastatic Breast Cancer
What this study did
NCT03591549 · Assiut University
2018-08-01 – 2021-10-01 · Metastatic Breast Cancer
What this study did
Other / comorbidity
NCT06523530 · Aristotle University Of Thessaloniki
2024-11-26 – 2027-10 · Metabolic Dysfunction-Associated Steatotic Liver Disease, Nonalcoholic Fatty Liver, Endometriosis
What this study did
NCT06455969 · Bradley Nindl
2024-07-15 – 2027-08 · Musculoskeletal Injury, Hypogonadism, Hormonal Contraception
What this study did
NCT05700903 · University of Colorado, Denver
2023-09-20 – 2025-07-16 · Androgen Deprivation Therapy, Prostate Cancer, Hypertension, Autonomic Dysfunction, Renal Disease
What this study did
NCT04248621 · Wonju Severance Christian Hospital
2020-01-23 – 2022-12-31 · Prostatic Neoplasms
What this study did
NCT03971110 · AstraZeneca
2021-01-28 – 2022-11-09 · Advanced Prostate Cancer
What this study did
NCT05013242 · Mansoura University
2020-12-25 – 2021-12-25 · Endometriosis
What this study did
NCT05304169 · Zodiac Produtos Farmaceuticos S.A.
2017-11-14 – 2020-06-15 · Prostate Cancer
What this study did
NCT01738724 · University of Sao Paulo
2012-01 – 2017-12 · Uterine Leiomyoma
What this study did
NCT00293670 · Tampere University
1997-05 – 2015-04 · Patients With T1-4 Advanced Prostate Cancer
What this study did
NCT01682642 · AZ Jan Palfijn Gent
2012-03 – 2014-10 · Infertility, Endometriosis
What this study did
NCT00851461 · Ramathibodi Hospital
2008-04 – 2013-11 · Spinobulbar Muscular Atrophy, Kennedy's Disease
What this study did
NCT00654524 · Zhejiang University
2008-03 – 2010-12 · Endometriosis
What this study did
NCT00746031 · University of Edinburgh
2008-12 – 2010-09 · Fibroid, Leiomyoma
What this study did
NCT00255268 · AstraZeneca
started 2004-08 · Metastatic Prostate Cancer
What this study did
NCT00286351 · Rigshospitalet, Denmark
started 2005-01 · Endometriosis
What this study did
NCT00293696 · Tampere University
2004-10 – 2006-11 · Prostate Cancer
What this study did
Early phase / not applicable (14)
HR+/HER2- Metastatic Breast Cancer
NCT00827307 · Zhejiang Cancer Hospital
2008-06 – 2011-08 · Mammography, Estrogen, Lipemia, Endometrium, Ultrasonography
What this study did
NCT00031850 · Institute of Cancer Research, United Kingdom
2000-03 – 2007-05 · Breast Cancer
What this study did
Other / comorbidity
NCT07552480 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2026-05-01 – 2027-10-01 · Allogeneic Haematopoietic Stem Cell Transplantation, Malignant Hematologic Disease, Ovarian Insufficiency
What this study did
NCT07552506 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2026-05-01 – 2027-10-01 · Aplastic Anaemia (AA), Allogeneic Haematopoietic Stem Cell Transplantation, Ovarian Insufficiency
What this study did
NCT07552493 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2026-05-01 – 2027-10-01 · Ovarian Insufficiency, Autologous Hematopoietic Stem Cell Transplantation
What this study did
NCT02346253 · Stanford University
2015-01-13 – 2026-05-17 · Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
What this study did
NCT05898321 · Women's Hospital School Of Medicine Zhejiang University
2023-06-01 – 2025-12-30 · Submucous Leiomyoma of Uterus
What this study did
NCT03440879 · Norwegian School of Sport Sciences
2018-09-21 – 2023-03-02 · Prostate Cancer, Resistance Exercise, Androgen Deprivation Therapy
What this study did
NCT02779387 · Peking University People's Hospital
2016-05 – 2021-05 · Infertility Associated With Endometriosis
What this study did
NCT00114114 · Massachusetts General Hospital
2004-09 – 2017-11-01 · Healthy Volunteers
What this study did
NCT02661789 · Gitte Moos Knudsen
2011-01 – 2012-12 · Postpartum Depression, Major Depressive Disorder, Postpartum Psychosis, Menopause, Neurodegeneration, Schizophrenia
What this study did
NCT00433173 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2006-05 – 2011-03 · Metabolic Syndrome
What this study did
NCT00536653 · Wirral University Teaching Hospital NHS Trust
1999-10 – 2007-01 · Osteoporosis
What this study did
Used as active comparator (20)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (10)
Other / comorbidity
NCT00303784 · University College, London
2006-03 – 2021-08 · Anemia, Cardiovascular Complications, Hot Flashes, Osteoporosis, Prostate Cancer
What this study did
NCT01964170 · Astellas Pharma Inc
2013-08-13 – 2016-08-08 · Prostate Cancer
What this study did
NCT01744366 · Ferring Pharmaceuticals
2013-01 – 2015-05 · Prostate Cancer
What this study did
NCT01242748 · Ferring Pharmaceuticals
2010-10 – 2012-01 · Prostate Cancer
What this study did
NCT00833248 · Ferring Pharmaceuticals
2009-04 – 2011-09 · Prostate Cancer
What this study did
NCT00884273 · Ferring Pharmaceuticals
2009-08 – 2011-03 · Prostate Cancer
What this study did
NCT00946920 · Ferring Pharmaceuticals
2009-06 – 2011-03 · Prostate Cancer
What this study did
NCT00831233 · Ferring Pharmaceuticals
2009-04 – 2010-07 · Prostate Cancer
What this study did
NCT01394263 · Endo USA Inc., a Keenova Therapeutics Company
2000-05 – 2003-12 · Prostate Cancer, Adenocarcinoma of the Prostate
What this study did
NCT00841113 · Speciality European Pharma Limited
1999-01 – 2003-02 · Prostate Cancer
What this study did
Phase 2 (6)
Other / comorbidity
NCT06378866 · Mayo Clinic
2024-06-03 – 2031-02-28 · Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer, Castration-resistant Prostate Cancer, Biochemically Recurrent Prostate Carcinoma
What this study did
NCT03899077 · Cancer Research Antwerp
2019-04-05 – 2025-12 · Cancer of Prostate
What this study did
NCT02278185 · University of Colorado, Denver
2015-11-11 – 2024-07-18 · Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
What this study did
NCT02107391 · SOTIO a.s.
2012-03 – 2016-06 · Prostate Cancer
What this study did
NCT00167648 · University of Washington
2005-03 – 2006-12 · Cancer, Prostate Neoplasms
What this study did
Phase 1 (2)
Other / comorbidity
NCT03450109 · Luye Pharma Group Ltd.
2017-12-22 – 2018-10-30 · Cancer of Prostate
What this study did
NCT02592031 · Merckle GmbH
2009-02 – 2009-12 · Bioequivalence
What this study did
Phase 4 (2)
Other / comorbidity
NCT01673984 · Ipsen
2012-08 – 2014-02 · Prostate Cancer
What this study did
NCT02749825 · Pharmatech
2002-09 – 2006-07 · Prostate Cancer
What this study did
Appears in other studies (15)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (6)
HR+/HER2- Metastatic Breast Cancer
NCT01674140 · SWOG Cancer Research Network
2013-09-12 – 2030-01 · Breast Cancer
What this study did
NCT02115282 · National Cancer Institute (NCI)
2014-03-29 – 2027-06-02 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, HER2/Neu Negative, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma
What this study did
NCT03423199 · National Cancer Center, Japan
2018-02-09 – 2025-09 · Breast Neoplasms
What this study did
NCT02278120 · Novartis Pharmaceuticals
2014-11-20 – 2023-04-20 · Advanced Metastatic Breast Cancer
What this study did
Other / comorbidity
NCT04484818 · ECOG-ACRIN Cancer Research Group
2021-03-01 – 2028-05-31 · Prostate Carcinoma
What this study did
NCT04455750 · Alliance for Clinical Trials in Oncology
2021-10-14 – 2027-09 · Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT02685397 · Sir Mortimer B. Davis - Jewish General Hospital
2016-10 – 2041-08 · Castration-resistant Prostate Cancer Patients with Oligometastases
What this study did
Phase 2 (4)
HR+/HER2- Metastatic Breast Cancer
NCT05607004 · Atossa Therapeutics, Inc.
2023-02-14 – 2027-04 · Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer
What this study did
NCT03671330 · Novartis Pharmaceuticals
2018-08-29 – 2025-05-09 · Breast Cancer
What this study did
Other / comorbidity
NCT07179939 · Fudan University
2025-09-10 – 2031-12-30 · HER2-positive Breast Cancer
What this study did
NCT02678520 · University of Kansas Medical Center
2015-12 – 2016-02 · Prostate Cancer
What this study did
Phase 1 (1)
HR+/HER2- Metastatic Breast Cancer
NCT05870579 · Novartis Pharmaceuticals
2023-11-13 – 2032-05-27 · Breast Cancer
What this study did
Early phase / not applicable (3)
Other / comorbidity
NCT04894188 · National Taiwan University Hospital
2022-01-27 – 2041-07-01 · Prostate Cancer
What this study did
NCT06636591 · Fudan University
2024-12-23 – 2026-06-30 · Breast Cancer Female, HER2-negative Breast Cancer
What this study did
NCT02594072 · University of British Columbia
2016-04 – 2024-12 · Prostate Cancer
What this study did

Competitive landscape

This drug's own stage for HR+/HER2- Metastatic Breast Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Goserelin: this drugApprovedPeptideGnRH receptor (agonist)not yet gradedNo reviewed efficacy summary in this indication
Abemaciclib (Verzenio)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02107703: Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4)
NCT02102490: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)): Abemaciclib 19.7% (95% CI 13.3 to 27.5)
Alpelisib (BYL719)ApprovedSmall moleculePI3K-alphaReliable signal
NCT02437318: Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant 11 Months (95% CI 7.49 to 14.52) vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant 5.7 Months (95% CI 3.65 to 7.36)
AnastrozoleApprovedSmall moleculeAromatasenot yet graded
NCT00291759: Recurrence-free survival, 2yr tamoxifen then 3yr anastrozole vs 5yr tamoxifen: HR 0.80 (95% CI 0.63-1.01), P=.06 (not statistically significant) missed phase 3 result · pivotal pending
NCT00300508: At a median follow-up of 62.3 months, women who received anastrozole (n=387) had a statistically significantly reduced risk of recurrence (locoregional recurrence, contralateral breast cancer or distant metastasis) versus women who received no further treatment (n=469): hazard ratio 0.62 (95% CI 0.40-0.96), P=.031. phase 3 result · pivotal pending
Camizestrant (Etcamah)ApprovedSmall moleculeEstrogen receptorReliable signal
NCT04964934: SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001
NCT04588298: Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81)
Capecitabine
ApprovedUS marketing discontinued
Small moleculeFluoropyrimidine (antimetabolite)not yet gradedNo reviewed efficacy summary in this indication
CapivasertibApprovedSmall moleculeAKT (inhibitor)Reliable signal
NCT04305496: Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.): Capivasertib + Fulvestrant (Global + China Cohort) 7.2 Months (95% CI 5.5 to 7.4) vs Placebo + Fulvestrant (Global + China Cohort) 3.6 Months (95% CI 2.8 to 3.7)
NCT01625286: Progression-free survival, Part B (randomized vs placebo + paclitaxel): median 10.9 months (95% CI 8.3 to 12.4) with capivasertib vs 8.4 months (95% CI 8.2 to 10.8) with placebo; HR 0.80 (95% CI 0.60 to 1.06), p=0.308 (CT.gov posted results). missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT05104866: Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)Partial signal
NCT00002662: ORR (the registered first objective) 32% vs 25% (P=.10); OS 15.4 vs 12.7 months (P=.03) and TTP 5.7 vs 3.6 months (P<.0001) favored docetaxel. missed
ElacestrantApprovedSmall moleculeEstrogen receptorPartial signal
NCT03778931: Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14)
Eribulin MesylateApprovedSmall moleculeTubulin / microtubulesPartial signal
NCT02225470: Progression-Free Survival, eribulin vs vinorelbine (independent tumor assessment): HR 0.80 (95% CI 0.65-0.98, P=0.036) in favor of eribulin; median PFS 2.8 months in both arms
NCT00337103: Co-primary endpoints, eribulin (n=554) vs capecitabine (n=548): overall survival median 15.9 vs 14.5 months, HR 0.88 (95% CI 0.77 to 1.00), P = .056; progression-free survival median 4.1 vs 4.2 months, HR 1.08 (95% CI 0.93 to 1.25), P = .30 (Kaufman et al., J Clin Oncol 2015). missed
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Weak signal
NCT02511639: Median progression-free survival: 9.9 months (everolimus + aromatase inhibitor) vs 7.2 months (aromatase inhibitor alone); HR 0.764 (95% CI 0.501-1.164)
NCT00863655: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. (date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to about 19 months): Everolimus + Exemestane 6.93 months (95% CI 6.44 to 8.05) vs Placebo + Exemestane 2.83 months (95% CI 2.76 to 4.14)
ExemestaneApprovedSmall moleculeAromatasePartial signal
NCT00002777: Objective response rate: 46% exemestane vs 31% tamoxifen (odds ratio 1.85, 95% CI 1.21-2.82, P=.005). Median progression-free survival (the trial's primary endpoint): 9.9 months exemestane vs 5.8 months tamoxifen; long-term log-rank P=.121 (not statistically significant). missed
Fulvestrant (Faslodex)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT01602380: Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59)
NCT00099437: Progression-free survival: fulvestrant 500 mg (n=362) vs 250 mg (n=374), HR 0.80 (95% CI 0.68 to 0.94), P = .006; CT.gov median time to progression 6.5 vs 5.5 months (Di Leo et al., J Clin Oncol 2010).
Gedatolisib (Revtorpyk)ApprovedSmall moleculePI3K (class I isoforms) and mTORC1/mTORC2Partial signal
NCT05501886: VIKTORIA-1 (NCT05501886), PIK3CA wild-type cohort, primary endpoint PFS: gedatolisib+fulvestrant+palbociclib (triplet) median PFS 9.3 months vs fulvestrant alone 2.0 months, HR 0.24 (95% CI 0.17-0.35), p<0.0001; gedatolisib+fulvestrant (doublet) median PFS 7.4 months, HR 0.33 (95% CI 0.24-0.48), p<0.0001.
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Weak signal
NCT00128310: Median progression-free survival: 6.0 months (gemcitabine + vinorelbine) vs 4.0 months (vinorelbine alone); hazard ratio 0.66 (p=0.0028). Overall survival not significantly different (15.9 vs 16.4 months, p=0.8046)
NCT00006459: Eli Lilly's pivotal phase III global registration trial of gemcitabine + paclitaxel vs paclitaxel alone in anthracycline-pretreated advanced breast cancer, matching this listing's title/sponsor. Primary endpoint (overall survival): 18.6 vs 15.8 months, HR 0.78 (95% CI 0.64-0.96), p=0.0187, favoring the gemcitabine combination.
Imlunestrant (Inluriyo)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT04975308: Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001
Inavolisib (Itovebi)ApprovedSmall moleculePI3K-alphaReliable signal
NCT04191499: Progression-Free Survival (PFS) (Up to 3.7 years): Inavo+Palbo+Fulv 15 months (95% CI 11.3 to 20.5) vs Pbo+Palbo+Fulv 7.3 months (95% CI 5.6 to 9.3)
IxabepiloneApprovedSmall moleculeMicrotubules (tubulin)Partial signalFeatured results are non-efficacy only in this race
LetrozoleApprovedSmall moleculeAromatasenot yet graded
NCT00003140: Estimated 4-year disease-free survival: letrozole 93% vs placebo 87% (75 vs 132 recurrences/new cancers out of 5187 enrolled); P<=0.001 phase 3 result · pivotal pending
NCT00004205: Disease-free survival (primary endpoint), letrozole vs tamoxifen: 5-year DFS 84.0% vs 81.4%; HR 0.81 (95% CI 0.70-0.93), P=0.003, at median follow-up 25.8 months (351 vs 428 events; N=8010). phase 3 result · pivotal pending
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00785291: Progression Free Survival (Time from randomization to progression or death due to any cause, whichever occurs first (up to 5 years)): Arm B (Nab-paclitaxel) 9.3 months (95% CI 8.15 to 10.45) vs Arm A (Paclitaxel) 10.97 months (95% CI 9.79 to 12.42) vs Arm C (Ixabepilone) 7.36 months (95% CI 6.21 to 8.18) missed
OlaparibApprovedSmall moleculePARPPartial signal
NCT02000622: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Olaparib 300 mg bd 7 Months (95% CI 5.7 to 8.3) vs Chemotherapy 4.2 Months (95% CI 2.8 to 4.3)
NCT03286842: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants (At every visit until the earliest of disease progression, death or end of study (up to 3 years)): Olaparib gBRCAm Cohort 8.18 months (95% CI 6.97 to 9.17)
Palbociclib (Ibrance)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02297438: Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6)
NCT01740427: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization date to date of first documentation of progression or death (up to approximately 2.5 years)): Palbociclib Plus Letrozole 24.8 Months vs Placebo Plus Letrozole 14.5 Months (95% CI 12.9 to 17.1)
RibociclibApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02422615: Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3)
NCT02278120: Progression Free Survival (PFS) by Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 29 months): Ribociclib + NSAI/Tamoxifen + Goserelin 23.8 Months vs Placebo + NSAI/Tamoxifen+ Goserelin 13 Months (95% CI 11 to 16.4)
Sacituzumab GovitecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT03901339: Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4)
TalazoparibApprovedSmall moleculePARPPartial signal
NCT01945775: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Talazoparib 8.6 months (95% CI 7.2 to 9.3) vs Physician's Choice Treatment 5.6 months (95% CI 4.2 to 6.7)
Tamoxifen (Soltamox)ApprovedSmall moleculeEstrogen receptornot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Partial signal
NCT04494425: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9)
NCT03734029: Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer (From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years): Trastuzumab Deruxtecan (T-DXd) 10.1 months (95% CI 9.5 to 11.5) | Physician's Choice 5.4 months (95% CI 4.4 to 7.1)
Vepdegestrant (Veppanu)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT05654623: PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025).
NCT04072952: Clinical benefit rate 38% (total n=71), the trial's primary endpoint (VERITAC expansion); CBR 51.2% in ESR1-mutant patients (n=41)
AfuresertibPhase 3Small moleculeAKT (inhibitor)Partial signal
NCT04851613: Primary endpoint, progression-free survival: median 7.6 months with afuresertib plus fulvestrant vs 2.0 months with placebo plus fulvestrant (sponsor topline, 2026-04-15).
Anbenitamab RepodatecanPhase 3Antibody–drug conjugateHER2 (biparatopic — extracellular domains II and IV)not yet gradedNo reviewed efficacy summary in this indication
AtirmociclibPhase 3Small moleculeCDK4Partial signal
NCT06465368: Percentage of Participants With Complete Cell Cycle Arrest (CCCA) at Day 14 (Day 14): PF-07220060 + Letrozole 88.2% (95% CI 76.6-94.5) vs Letrozole Alone 17.9% (95% CI 10.0-29.8)
BEBT-209Phase 3Small moleculeCDK4 (selective)not yet gradedNo reviewed efficacy summary in this indication
Beruzatatug PelitecanPhase 3Antibody–drug conjugateHER3not yet gradedNo reviewed efficacy summary in this indication
BGB-43395Phase 3Small moleculeCDK4not yet gradedNo reviewed efficacy summary in this indication
BireociclibPhase 3Small moleculeCDK2/4/6Reliable signal
NCT05077449: BRIGHT-2 (NCT05077449), primary endpoint median PFS: bireociclib (XZP-3287) + fulvestrant 14.7 months vs placebo + fulvestrant 7.3 months; HR 0.54 (95% CI 0.40-0.74); p<0.001
ChidamidePhase 3Small moleculeHDACReliable signal
NCT02482753: Investigator-assessed median PFS: 7.4 months (95% CI 5.5-9.2) chidamide+exemestane vs 3.8 months (95% CI 3.7-5.5) placebo+exemestane; hazard ratio 0.755, p=0.0336
CulmerciclibPhase 3Small moleculeCDK2/CDK4/CDK6, CDK2/4/6/CDK4Partial signal
NCT05375461: Median investigator-assessed PFS: 16.6 months (culmerciclib + fulvestrant) vs 7.5 months (placebo + fulvestrant); HR 0.36 (95% CI 0.26-0.51), P<0.001, meeting the primary endpoint.
DalpiciclibPhase 3Small moleculeCDK4 and CDK6not yet gradedNo reviewed efficacy summary in this indication
Denosumab (Xgeva)Phase 3Monoclonal antibodyRANKLnot yet gradedNo reviewed efficacy summary in this indication
Disitamab VedotinPhase 3Antibody–drug conjugateHER2Partial signal
NCT03052634: Confirmed ORR at 2.0 mg/kg Q2W: 42.9% (9/21) in HER2-overexpression and 33.3% (22/66) in HER2-low advanced breast cancer; median PFS 5.7 and 5.1 months
GiredestrantPhase 3Small moleculeEstrogen receptorPartial signal
NCT04546009: persevERA (NCT04546009), primary endpoint investigator-assessed PFS: giredestrant plus palbociclib median PFS 33.1 months vs letrozole plus palbociclib 28.2 months; HR 0.89 (95% CI 0.76-1.05); p=.1553. missed
HRS-6209Phase 3Small moleculeCDK4not yet gradedNo reviewed efficacy summary in this indication
HRS-8080Phase 3Small moleculeEstrogen receptor (degrader)not yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
JS105Phase 3Small moleculePI3K-alpha (mutant-selective)not yet gradedNo reviewed efficacy summary in this indication
NTQ1062Phase 3Small moleculeAKT (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
PalazestrantPhase 3Small moleculeEstrogen receptorWeak signalNo reviewed efficacy summary in this indication
Patritumab DeruxtecanPhase 3Antibody–drug conjugateHER3Weak signalNo reviewed efficacy summary in this indication
PembrolizumabPhase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
PrifetrastatPhase 3Small moleculeKAT6A / KAT6Bnot yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
SaruparibPhase 3Small moleculePARP1 inhibitor (next-gen)not yet gradedNo reviewed efficacy summary in this indication
SHR-6209Phase 3Small moleculeCDK4not yet gradedNo reviewed efficacy summary in this indication
Sirolimus For Injection (Albumin-Bound)Phase 3Small moleculemTOR (mechanistic target of rapamycin complex 1), via FKBP-12not yet gradedNo reviewed efficacy summary in this indication
TaragarestrantPhase 3Small moleculeEstrogen receptornot yet gradedNo reviewed efficacy summary in this indication
TersolisibPhase 3Small moleculePI3K-alpha (mutant-selective, allosteric)not yet gradedNo reviewed efficacy summary in this indication
Tibremciclib (Kangmeina)Phase 3Small moleculeCDK4 and CDK6Partial signal
NCT05433480: Investigator-assessed PFS: tibremciclib plus fulvestrant median 16.5 months (95% CI 12.8 to 16.6) vs placebo plus fulvestrant 5.6 months (95% CI 4.5 to 9.2); HR 0.37 (95% CI 0.27 to 0.52), P<.001
Trastuzumab PamirtecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
UtidelonePhase 3Small moleculeTubulin / microtubulesnot yet gradedNo reviewed efficacy summary in this indication

Large race: only the 60 furthest-along competitors are listed; 45 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(27 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Goserelin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Triple Negative Breast Cancer, Premenopausal Breast CancerRecruiting
Est. primary completion 2026-12 · NCT06225284 · CT.gov ↗
What to watch
2027 (11)
January 2027 (1)
Phase 2Breast Cancer, Cancer of Breast, Breast Neoplasms, Cancer of the BreastRecruiting
Est. primary completion 2027-01-31 · NCT02476786 · CT.gov ↗
What to watch
February 2027 (1)
Phase 2Prostate Adenocarcinoma, Recurrent Prostate CarcinomaActive not recruiting
Est. primary completion 2027-02-01 · NCT01786265 · CT.gov ↗
What to watch
March 2027 (1)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-03-30 · NCT07310420 · CT.gov ↗
What to watch
April 2027 (1)
Phase 4Metabolic Dysfunction-Associated Steatotic Liver Disease, Nonalcoholic Fatty Liver, EndometriosisActive not recruiting
Est. primary completion 2027-04 · NCT06523530 · CT.gov ↗
What to watch
May 2027 (3)
Early phase / not applicableAllogeneic Haematopoietic Stem Cell Transplantation, Malignant Hematologic Disease, Ovarian InsufficiencyNot yet recruiting
Est. primary completion 2027-05-01 · NCT07552480 · CT.gov ↗
What to watch
Early phase / not applicableAplastic Anaemia (AA), Allogeneic Haematopoietic Stem Cell Transplantation, Ovarian InsufficiencyNot yet recruiting
Est. primary completion 2027-05-01 · NCT07552506 · CT.gov ↗
What to watch
Early phase / not applicableOvarian Insufficiency, Autologous Hematopoietic Stem Cell TransplantationNot yet recruiting
Est. primary completion 2027-05-01 · NCT07552493 · CT.gov ↗
What to watch
August 2027 (3)
Phase 4Musculoskeletal Injury, Hypogonadism, Hormonal ContraceptionRecruiting
Est. primary completion 2027-08 · NCT06455969 · CT.gov ↗
What to watch
Phase 2Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8 …Recruiting
Est. primary completion 2027-08-23 · NCT04734730 · CT.gov ↗
What to watch
Phase 2Prostate CancerRecruiting
Est. primary completion 2027-08-31 · NCT06582446 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer …Recruiting
Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗
What to watch
2028 (5)
January 2028 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-01-01 · NCT07158021 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Salivary Gland Carcinoma, Precision TherapyRecruiting
Est. primary completion 2028-07-10 · NCT06145308 · CT.gov ↗
What to watch
September 2028 (2)
Phase 1/2Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder, Hormone Receptor Positive Breast Carcinoma, Breast CancerNot yet recruiting
Est. primary completion 2028-09 · NCT07596212 · CT.gov ↗
What to watch
Phase 2Invasive Breast Cancer (Stage I-III)Not yet recruiting
Est. primary completion 2028-09-30 · NCT07801898 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-21 · NCT07460752 · CT.gov ↗
What to watch
2029 (2)
January 2029 (1)
Phase 2Breast NeoplasmsRecruiting
Est. primary completion 2029-01 · NCT07287098 · CT.gov ↗
What to watch
September 2029 (1)
Phase 3Early Breast CancerActive not recruiting
Est. primary completion 2029-09-07 · NCT05827081 · CT.gov ↗
What to watch
2030 (3)
June 2030 (1)
Phase 4HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2030-06-28 · NCT05161195 · CT.gov ↗
What to watch
July 2030 (1)
Phase 2/3Prostate CancerRecruiting
Est. primary completion 2030-07-31 · NCT06282588 · CT.gov ↗
What to watch
September 2030 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-09 · NCT06953882 · CT.gov ↗
What to watch
2032 (1)
December 2032 (1)
Phase 3Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8Recruiting
Est. primary completion 2032-12-31 · NCT04423211 · CT.gov ↗
What to watch
2033 (2)
April 2033 (1)
Phase 3Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8 …Recruiting
Est. primary completion 2033-04-01 · NCT03678025 · CT.gov ↗
What to watch
December 2033 (1)
Phase 3Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8Active not recruiting
Est. primary completion 2033-12-31 · NCT04513717 · CT.gov ↗
What to watch
2034 (1)
July 2034 (1)
Phase 2Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, Breast CancerRecruiting
Est. primary completion 2034-07-01 · NCT06348134 · CT.gov ↗
What to watch
2035 (1)
December 2035 (1)
Phase 3High Risk Prostate CancerNot yet recruiting
Est. primary completion 2035-12 · NCT07777263 · CT.gov ↗
What to watch

See the full readout calendar ↗